MET and hepatocellular carcinoma: Trivantinib, another competitive inhibitor of c-MET, was tested in a phase-III, randomized, placebo-controlled trial, failed to improve OS compared to placebo in patients with MET-high advanced HCC already treated with sorefenib [55].